BCR and systemic lupus erythematosus: Given BTK’s key involvement in BCR signaling, its inhibition presents an attractive therapeutic approach for autoimmune diseases involving abnormal B cell function, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), or multiple sclerosis (MS).